BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
MINNEAPOLIS, March 15, 2011 /PRNewswire/ -- BioDrain Medical, Inc. (OTC Bulletin Board: BIOR), producer of the FDA cleared Streamway™ System for automated surgical fluid disposal, announced today that it has retained Consulting for Strategic Growth 1 ("CFSG1") as its U.S. Investor Relations representative. Stan Wunderlich, Chairman and CEO of CFSG1, and his team will immediately initiate a proactive Investor Relations campaign in order to drive investor awareness of BioDrain's proprietary surgical fluid management system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and the related germs, viruses and diseases that are potentially found in the surgical environment.
"We are very excited to work with CFSG1 to enhance our visibility to the investment community as we introduce our game-changing product to the market," said Kevin Davidson, President of BioDrain Medical. "In addition, we are entering a very exciting stage in the Company's development as more hospitals recognize the financial, environmental and operational benefits of our system and we are very pleased to have a partner with extensive experience in bringing early-stage public companies to the forefront of the U.S. investment community."
Stan Wunderlich, commented, "BioDrain has already established itself as a competitive player within the fluid management system arena. The Company's patented system makes the operating room and our environment, safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. Wall Street will be learning more about their core businesses and continued progress."
CFSG1 has decades of hands-on corporate development experience combi